Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
System-State: Number of processed items 35.587 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US37733W2044
State: 02.04.2025 | 6AM
Do you already know our new terminal view? Click here.
FIGI: BBG000BLB481
GSK
GSK plc
GICS: - · Sector: Healthcare · Sub-Sector: Drug Manufacturers - General
NAME
GSK plc
ISIN
US37733W2044
TICKER
GSK
MIC
XNYS
REUTERS
GSK.N
BLOOMBERG
GSK US
Mon, 17.02.2025       GSK
US37733W2044

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSE: GSK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the f...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Wed, 12.02.2025       GSK
US37733W2044

Glancy Prongay & Murray LLP reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (t...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Tue, 11.02.2025       GSK
US37733W2044

Law Offices of Howard G. Smith reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). IF YOU AR...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Tue, 11.02.2025       GSK
US37733W2044

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). GSK investors have until April 7, 2025 to file a lead plaintiff...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Mon, 10.02.2025       GSK
US37733W2044

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusiv...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Sun, 09.02.2025       GSK
US37733W2044

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSE: GSK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the f...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Fri, 07.02.2025       GSK
US37733W2044

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). GSK investors have until April 7, 2025 to file a lead plaintiff m...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Thu, 06.02.2025       GSK
US37733W2044

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc (“GSK” or “the Company”) (NYSE: GSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchas...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Thu, 06.02.2025       GSK
US37733W2044

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GSK plc. (“GSK” or the “Company”) (NYSE: GSK) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON GSK PLC. (GSK), CLICK HE...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Wed, 05.02.2025       GSK
US37733W2044

Law Offices of Howard G. Smith announces an investigation on behalf of GSK plc. (“GSK” or the “Company”) (NYSE: GSK) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GSK PLC. (GSK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOV...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Wed, 05.02.2025       GSK
US37733W2044

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”). For more information, submit a form, email attorney Phillip Kim, or g...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Wed, 05.02.2025       GSK
US37733W2044

The Law Offices of Frank R. Cruz announces an investigation of GSK plc. (“GSK” or the “Company”) (NYSE: GSK) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON GSK PLC. (GSK), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink
Mon, 09.12.2024       GSK
US37733W2044

GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the DREAMM-7 trial evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone (BVd) versus daratumumab in combination with bortezomib plus dexamethasone (DVd) as a secon...
Read More
GSK
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.